Bristol-Myers Squibb Co. (BMY)

50.60
0.28 0.55
NYSE : Health Technology
Prev Close 50.88
Open 50.52
Day Low/High 49.83 / 51.03
52 Wk Low/High 49.96 / 70.05
Volume 15.37M
Avg Volume 6.04M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 88.61B
EPS 0.60
P/E Ratio 226.25
Div & Yield 1.60 (2.84%)

Latest News

Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises

Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises

Stocks are mixed after rising earlier in the session following a rally in China that saw stocks soar to their biggest single-day gain in nearly three years.

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Results In Significantly Longer Treatment-Free Survival In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Results In Significantly Longer Treatment-Free Survival In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced the results of a new analysis from the Phase 3 CheckMate -214 study, demonstrating that therapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or...

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits In Patients With Advanced Melanoma

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits In Patients With Advanced Melanoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of...

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit In Previously Untreated Patients With MSI-H Or DMMR Metastatic Colorectal Cancer

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit In Previously Untreated Patients With MSI-H Or DMMR Metastatic Colorectal Cancer

Bristol-Myers Squibb Company (NYSE: BMY) today announced new data from a cohort of the CheckMate -142 study in which Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) demonstrated durable clinical benefit as a first-line treatment in patients with...

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Shows Promising Results In Patients With Advanced Form Of Bladder Cancer

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Shows Promising Results In Patients With Advanced Form Of Bladder Cancer

Bristol-Myers Squibb Company (NYSE: BMY) today announced follow-up data evaluating Opdivo (nivolumab) monotherapy and Opdivo in combination with Yervoy (ipilimumab) in patients with platinum-pretreated metastatic urothelial carcinoma (mUC).

Bristol-Myers Squibb Provides Update On The Ongoing Regulatory Review Of Opdivo Plus Low-Dose Yervoy In First-Line Lung Cancer Patients With Tumor Mutational Burden ≥10 Mut/Mb

Bristol-Myers Squibb Provides Update On The Ongoing Regulatory Review Of Opdivo Plus Low-Dose Yervoy In First-Line Lung Cancer Patients With Tumor Mutational Burden ≥10 Mut/Mb

Bristol-Myers Squibb Company (NYSE:BMY) announced updates regarding regulatory actions by health authorities in the United States (U.

Bristol-Myers Squibb To Showcase Immunoscience Research And Biomarker-Guided Treatment Approaches At The 2018 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb To Showcase Immunoscience Research And Biomarker-Guided Treatment Approaches At The 2018 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb Company (NYSE:BMY) today announced that 28 abstracts related to ORENCIA ® (abatacept) and the Company's immunoscience pipeline will be presented at the 2018 American College of Rheumatology and Association of Rheumatology Health...

Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint Of Overall Survival With Opdivo Versus Chemotherapy In Patients With Previously Treated Relapsed Small Cell Lung Cancer

Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint Of Overall Survival With Opdivo Versus Chemotherapy In Patients With Previously Treated Relapsed Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin (where approved), in patients with small cell lung...

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

NEW YORK and HOLON, Israel, Oct. 11, 2018 /PRNewswire/ --  Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of...

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in...

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its CEO to hear about her journey and how immunotherapies are taking the lead.

Consider These Diagnostic Testing Firms

Consider These Diagnostic Testing Firms

Diagnostic firms can have an advantage of recurring revenue streams.

European Medicines Agency Validates Bristol-Myers Squibb's Application For Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone In Patients With Multiple Myeloma

European Medicines Agency Validates Bristol-Myers Squibb's Application For Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone In Patients With Multiple Myeloma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated the Company's type II variation application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone (EPd) for...

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty cents ($0.

Bristol-Myers Squibb's Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance In Patients With Moderate To Severe Plaque Psoriasis In Phase 2 Trial

Bristol-Myers Squibb's Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance In Patients With Moderate To Severe Plaque Psoriasis In Phase 2 Trial

Bristol-Myers Squibb Company (NYSE:BMY) today announced results from a Phase 2 study of BMS-986165, an investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis.

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2018 Global Health Care Conference on Thursday, September 13, 2018, in New York.

Bristol-Myers Squibb To Announce Results For Third Quarter 2018 On October 25

Bristol-Myers Squibb To Announce Results For Third Quarter 2018 On October 25

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2018 on Thursday, October 25, 2018.

We Are Riding For Patients

We Are Riding For Patients

Today, for the fifth year in a row, Bristol-Myers Squibb Company (NYSE:BMY) is launching Coast 2 Coast 4 Cancer, a nearly month-long cross-country bike ride to raise money for cancer research.

(Photo: Business Wire)

(Photo: Business Wire)

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Christopher Boerner, Ph.

Here's Why You Should Invest in Immunotherapy Companies

Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.

Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying

Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying

Let's take a fresh look at the charts.

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

U.S. Food And Drug Administration Approves Opdivo® (nivolumab) As The First New Medication In Nearly 20 Years For Certain Patients With Previously Treated Small Cell Lung Cancer

U.S. Food And Drug Administration Approves Opdivo® (nivolumab) As The First New Medication In Nearly 20 Years For Certain Patients With Previously Treated Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) received approval from the U.

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) For The Adjuvant Treatment Of Adult Patients With Melanoma With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) For The Adjuvant Treatment Of Adult Patients With Melanoma With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone...

I See More Volatility Ahead

Although it would not surprise me if we see a rally attempt on Tuesday.

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2018, which were highlighted by strong sales for Eliquis (apixaban) and Opdivo (nivolumab), and important regulatory progress in the company's Immuno-Oncology...

TheStreet Quant Rating: C+ (Hold)